This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 1992 foundational study that first isolated an endogenous substance from the brain that binds to the cannabinoid receptor and established its structure. Researchers purified an active constituent from porcine brain tissue and identified it as arachidonoylethanolamide. It was named anandamide after the Sanskrit word for “bliss.” This was not the discovery of a cannabis constituent; it showed that animals also have an internal signaling substance that acts at cannabinoid receptors.
The discovery advanced understanding of the physiological regulatory system later called the endocannabinoid system. Binding to a receptor, however, and efficacy for a particular human disease are different levels of evidence. This paper was not a clinical trial; it was a biochemical study of a chemical derived from porcine brain.
Study design
Researchers fractionated lipid extracts from brain tissue and tracked activity using the ability to bind to the cannabinoid receptor. They purified the active fraction with chromatography and other methods, then determined its molecular structure through chemical analyses including mass spectrometry and nuclear magnetic resonance. Identification was checked by comparing the properties of a synthesized candidate with the natural extract.
They also examined receptor binding and functional responses and compared them with known cannabinoid actions. This method was suited to asking whether an endogenous ligand existed, but it could not simultaneously resolve changes in concentration in the living body, pathways of synthesis and degradation, roles across tissues, or effects on behavior and disease.
Content
Before this study, receptors to which THC binds were known to exist in the brain. The background hypothesis was that if the receptor existed through evolution, the body should produce its own natural signaling molecule rather than the receptor existing only for plant-derived THC. Identifying anandamide supplied a specific molecule for that hypothesis.
Anandamide is a lipid signaling molecule whose production, storage, and degradation differ from those of classical water-soluble neurotransmitters. Later research identified multiple endogenous cannabinoids, receptors, and synthetic and degradative enzymes, but the scope directly established by this paper needs to be distinguished from knowledge developed afterward.
Results
The isolated constituent bound to the cannabinoid receptor and showed pharmacological activity. Structural analysis indicated that it was an ethanolamide derived from arachidonic acid, and comparison with a synthetic standard also supported the identification. This provided direct chemical evidence that an endogenous cannabinoid-like ligand exists in the mammalian brain.
Importantly, even when an endogenous substance and plant-derived THC involve the same receptor, their strength, duration, distribution, and metabolism need not be identical. Recasting “the body has a similar system” as “external cannabis use is natural and safe” goes beyond the scope of the paper.
Limitations
The samples came from porcine brain, not human participants. Binding activity detected under extraction and purification conditions cannot directly predict everyday brain function or clinical outcomes. Early receptor assays also had the technical limitations of their period, and subsequent research was needed to confirm receptor subtypes, enzymes, and additional ligands.
The study also did not test benefits or harms from increasing anandamide concentrations. Claims about disease, treatment, or psychological experience require separate experimental and clinical evidence.
Safety
Foundational receptor research is not an evaluation of product safety or a guide to use. When an external substance acts on an endogenous signaling system, it does not necessarily reproduce physiological regulation in time, location, or concentration. The existence of a receptor alone cannot determine toxicity, dependence, mental-health effects, or interactions.
This page is intended to explain research history and mechanism; it does not guide ingestion or self-treatment. Safe interpretation requires not converting a biochemical discovery into medical assurance.
Source and rights
Original source: Devane WA, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–1949. DOI: 10.1126/science.1470919.
Respecting the publisher’s copyright, this page is a detailed introduction independently describing public bibliographic information, the abstract, and the study’s historical position. It is not a full translation or republication of figures and tables.